Publication: Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
Issued Date
2021-12-01
Resource Type
ISSN
14712261
Other identifier(s)
2-s2.0-85109179940
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMC Cardiovascular Disorders. Vol.21, No.1 (2021)
Suggested Citation
Wipharak Rattanavipanon, Thanyaluck Sotananusak, Fairus Yamaae, Arisa Chandrsawang, Pitchapa Kaewkan, Surakit Nathisuwan, Teerapat Yingchoncharoen Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis. BMC Cardiovascular Disorders. Vol.21, No.1 (2021). doi:10.1186/s12872-021-02145-9 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/77562
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
Other Contributor(s)
Abstract
Background: Treatment of heart failure with reduced ejection fraction (HFrEF) has been revolutionized by angiotensin receptor/neprilysin inhibitor (ARNI). ARNI has been shown to significantly reduce morbidity and mortality in a large, randomized controlled trial. However, real-world evaluation of ARNI with a diverse population is still limited. Methods: HFrEF patients receiving angiotensin receptor/neprilysin inhibitor (ARNI) or standard HF treatment at a university hospital in Thailand were prospectively followed-up from January 2015 to December 2019. The primary outcome was a composite of all-cause mortality and heart failure hospitalization. Survival analysis and the Cox proportional hazard model were used to compare clinical outcomes between the two groups. Results: During a follow-up period of 12 months, the primary outcome occurred in 10 patients in the ARNI group (11.5%) and 28 in the standard treatment group (28.0%) (hazard ratio 0.34; 95% CI: 0.15–0.80; p = 0.013). After adjustment for confounding factors, ARNI was significantly associated with a significant reduction in the primary outcome (HR 0.32, 95% CI: 0.13–0.82, p = 0.017). In addition, ARNI was also significantly associated with a decrease in the clinical signs and symptoms of HF, including dyspnea, orthopnea, and fatigue. Orthostatic hypotension was more frequently reported among the ARNI group than among the standard treatment group. The rates of target dose achievement were comparable between the two groups. Conclusion: In real-world practice, ARNI use was associated with a significant reduction in both clinical outcomes and symptom improvement, while orthostatic hypotension was more common in patients in the ARNI group than in patients in the standard treatment group.